L'esempio del rischio infettivo - Azienda USL Valle d'Aosta

More documents

Recommendations

Info

Infezioni e personale Infezione Pz–Pers.. Pers-Pz Tubercolosi basso / alto basso / alto Meningite M. raro ? Influenza medio medio HIV basso basso Epatite B basso raro Epatite C basso ? Wenzel, Prevention and Control of hospital Infections,1997
vious Pre Volume 336:178-185 January 16, 1997 Number 3 Next Transmission of Hepatitis B to Patients from Four Infected Surgeons without Hepatitis B e antigen The Incident Investigation Teams and Others ckground Transmission of hepatitis B virus (HBV) to patients by infected surgeons who carry patitis B e antigen (HBeAg) has been documented repeatedly. In the United Kingdom HBeAgsitive surgeons are not permitted to perform certain procedures that carry a risk that patients ight be exposed to the blood of a health care worker. There are no practice restrictions for carrier hepatitis B surface antigen without detectable HBeAg, unless transmission has been monstrated. Methods In four unconnected cases of acute hepatitis B, surgery was identified as a ssible source, so we tested the surgical teams for serologic markers of HBV infection. In each se a surgeon was found to be infected with the virus. HBV DNA was amplified by a nested lymerase chain reaction from serum from the four infected surgeons and the four patients, and ect nucleotide sequencing of two regions of the HBV genome was performed. Alternative source infection were ruled out. Other patients on whom three of the surgeons had recently performed ocedures were offered testing. Results All four surgeons were carriers of HBV, but none had tectable serum HBeAg. The nucleotide sequences of HBV DNA from the surgeons were istinguishable from those from the corresponding patients. The screening of other exposed tients identified at least two other patients who had probably acquired hepatitis B fection from one of these surgeons. Conclusions Surgeons who are carriers of HBV without
Page 1 and 2:
Sicurezza per operatori e pazienti
Page 3 and 4: Perché è necessario un sistema pe
Page 5 and 6: To Err Is Human Institute Of Medici
Page 8 and 9: methodology includes the following
Page 10 and 11: esident Signs Patient Safety and ua
Page 12 and 13: Worl Alliance for Patient Safety 20
Page 14 and 15: La Regione Piemonte Epidemiologia
Page 16 and 17: PREVALENZA DI HAI (att.ric.) Pazien
Page 18 and 19: Sorveglianza infezioni chirurgiche
Page 21 and 22: Costi per sito di infezione
Page 23: SARS Bird FLU prion
Page 26 and 27: Biofilm su catetere endotracheale
Page 28: I costi delle pratiche inutili Osp
Page 41 and 42: Tre sentenze della Corte di Cassazi
Page 43 and 44: Legge francese n. 303 del 4 marzo 2
Page 45 and 46: … quando tali danni sono direttam
Page 47 and 48: ap. II - Sez. II: procedure di comp
Page 49 and 50: 3. I RISCHI DEVONO ESSERE DICHIARAT
Page 51 and 52: La responsabilità alla azienda dat
Page 53: Infezioni e personale Infezione Pz-
Page 57 and 58: Rischio Biologico Ed Operatori Sani
Page 59 and 60: Rischio di sieroconversione Siop 19
Page 61 and 62: Le possibili risposte Può esister
Page 63 and 64: Infezioni ospedaliere scenario anni
Page 65 and 66: A D I Modello controllo infezioni R
Page 67: I programmi di prevenzione sono eff
Page 70 and 71: Tentativi di analisi economica… (
Page 72 and 73: Funzioni dell’ospedale (JCAHO, 19
Page 74 and 75: Surveillance, Surveillance Surveill
Page 76 and 77: Il metodo L’esempio della 626 L
Page 78 and 79: JCAHO 2005 Long Term Care Standard
Page 80 and 81: Prospettive Dei Programmi Di Preven
Page 82 and 83: Diffusione per regione degli ospeda
Page 84 and 85: Inghilterrra Gruppo di coordinamen
Page 86 and 87: Galles Per il 2005 viene chiesto l
Page 88 and 89: Francia Lo strumento operativo è
Page 90 and 91: Francia.In dettaglio le azioni rich
Page 92 and 93: Australia In primo luogo le attivit
Page 94 and 95: WHO Raccomandazioni
Page 97 and 98: Una rete regionale ben strutturata
Page 99 and 100: Discussione La prevenzione Hai è
Page 101 and 102: Discussione 3 Che rapporti tra Ris
Page 103 and 104: Siate trasparenti Parlate al cellul
Page 105 and 106:
Un Sistema Di Indicatori Chiaramen
Page 107 and 108:
Quale prevenzione?
Page 110 and 111:
Quale prevenzione?
show all

L'esempio del rischio infettivo - Azienda USL Valle d'Aosta

Create successful ePaper yourself

Delete template?

Save as template?